Search results for "Intratumor heterogeneity"

showing 4 items of 4 documents

Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

2018

Patient-derived xenografts (PDX) and the Avatar, a single PDX mirroring an individual patient, are emerging tools in preclinical cancer research. However, the consequences of intratumor heterogeneity for PDX modeling of biomarkers, target identification, and treatment decisions remain under-explored. In this study, we undertook serial passaging and comprehensive molecular analysis of neuroblastoma orthotopic PDXs, which revealed strong intrinsic genetic, transcriptional, and phenotypic stability for more than 2 years. The PDXs showed preserved neuroblastoma-associated gene signatures that correlated with poor clinical outcome in a large cohort of patients with neuroblastoma. Furthermore, we…

0301 basic medicineMaleProteomicsCancer ResearchGenotypeBiologyProteomicsPolymorphism Single NucleotideTranscriptomeTranslational Research Biomedical03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineIntratumor heterogeneityNeuroblastomamedicineBiomarkers TumorAnimalsHumansIn patientTumor xenograftNeoplasm StagingGene Expression ProfilingInfantmedicine.diseasePhenotypeGene expression profilingDisease Models Animal030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleTranscriptomeNeoplasm TransplantationCancer research
researchProduct

Precision sampling fuels precision oncology: an evolutionary perspective.

2021

Intratumor heterogeneity (ITH) develops in malignant tumors. Precision sampling that captures this tumor variability is essential for the implementation of precision oncology. We highlight the necessity to update current sampling protocols and implement a strategy to ensure ITH detection and characterization. A cost-effective strategy for such sampling has been modeled in clear cell renal cell carcinoma (CCRCC).

Cancer ResearchComputer sciencePerspective (graphical)Sampling (statistics)medicine.diseasecomputer.software_genreBiological EvolutionKidney NeoplasmsClear cell renal cell carcinomaOncologyIntratumor heterogeneityPrecision oncologymedicineHumansData miningPrecision MedicinecomputerCarcinoma Renal CellTrends in cancer
researchProduct

EXOSOMES DERIVED FROM METASTATIC COLON CANCER CELLS TRANSFER MALIGNANT PHENOTYPIC TRAITS TO SURROUNDING CELLS: THEIR EMERGING ROLE IN TUMOR HETEROGEN…

2018

Several studies have clearly demonstrated that within a heterogeneous tumor mass the inter-clonal cooperation between metastatic and non-metastatic cells can facilitate the tumor progression. Recent accumulating evidence has highlighted that tumor-derived exosomes (TDEs) play a relevant role as mediator of the inter-clonal collaborative cooperation affecting the properties of both tumor and non-tumor component. In this context, our goal was to understand if exosomes derived from highly metastatic cells may influence the behaviour of less aggressive tumor cells and the properties of endothelium. We found that metastatic SW620 cells transfer through exosomes (SW620Exos) their round/amoeboid p…

Tumor-derived esosomeSettore BIO/13 - Biologia Applicataintratumor heterogeneityamoeboid phenptype
researchProduct

Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment

2014

Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.

cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapyFrontiers in Oncology
researchProduct